Orsi Franco, Monfardini Lorenzo, Bonomo Guido, Krokidis Miltiadis, Della Vigna Paolo, Disalvatore Davide
Unit of Interventional Radiology, European Institute of Oncology , Milan , Italy .
Int J Hyperthermia. 2015 May;31(3):233-9. doi: 10.3109/02656736.2015.1004134. Epub 2015 Mar 11.
The aim of this study was to assess the safety and effectiveness of contrast-enhanced ultrasound (CEUS) on ultrasound guided high intensity focused ultrasound (USgHIFU) ablation of uterine fibroids.
Thirty-three patients (37 fibroids) were randomly assigned to two groups: group A (17 patients, 20 fibroids) in which CEUS was used before, during and after HIFU treatment, and group B (16 patients, 17 fibroids) in which CEUS was not administered at all. Follow-up including contrast-enhanced magnetic resonance imaging (MRI) and a clinical questionnaire was performed, and technical success, ablation efficacy, volume reduction and complications were assessed.
Technical success was 100% in both groups. CEUS revealed residual enhancement in 40% of the patients in group A and the treatment was continued until the completion of ablation. MRI at 1 month after treatment revealed significant difference in the relative fibroid volume reduction rate between the two groups: 16.1% in group A versus 4.8%, in group B (p = 0.01). There was no statistically significant relative volume reduction rate for the results at 3, 6 and 12 months and no significant changes in the quality of life results or the complication rate.
CEUS was safe and effective in enhancing US guidance during HIFU ablation of uterine fibroids. Moreover, the use of CEUS during HIFU sonication increased the ablation efficacy, leading to a more relevant fibroid volume reduction at 1 and 3 months. This gap disappeared after 6 months, when there were no differences between the two groups of patients at MRI. However, in our experience, USgHIFU represented a very effective method for the treatment of uterine fibroids, and the use of CEUS during HIFU procedure reduced the treatment time and treatment repetitions for incomplete fibroid ablation.
本研究旨在评估超声造影(CEUS)在超声引导高强度聚焦超声(USgHIFU)消融子宫肌瘤中的安全性和有效性。
33例患者(37个肌瘤)被随机分为两组:A组(17例患者,20个肌瘤)在HIFU治疗前、治疗期间和治疗后使用CEUS;B组(16例患者,17个肌瘤)完全不使用CEUS。进行包括增强磁共振成像(MRI)和临床问卷的随访,并评估技术成功率、消融效果、体积缩小情况和并发症。
两组的技术成功率均为100%。CEUS显示A组40%的患者有残余增强,治疗持续至消融完成。治疗后1个月的MRI显示两组间肌瘤相对体积缩小率有显著差异:A组为16.1%,B组为4.8%(p = 0.01)。3、6和12个月时的结果相对体积缩小率无统计学显著差异,生活质量结果或并发症发生率也无显著变化。
CEUS在HIFU消融子宫肌瘤过程中增强超声引导是安全有效的。此外,在HIFU超声治疗期间使用CEUS可提高消融效果,在1个月和3个月时导致肌瘤体积有更显著的缩小。6个月后这种差距消失,此时两组患者的MRI检查结果无差异。然而,根据我们的经验,USgHIFU是治疗子宫肌瘤的一种非常有效的方法;在HIFU治疗过程中使用CEUS可减少不完全肌瘤消融的治疗时间和治疗次数。